ELTX - NASDAQ

Elicio Therapeutics, Inc.

ELTX·NASDAQ

$12.53

+8.4%

HealthcareBiotechnology

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$239.15M

EPS-2.5800

P/E Ratio-4.86

Earnings Date08/06/2026

25.86M

Assets

-8%

3Y+14.0%

5Y-45.0%

10Y+134.0%

24.23M

Total Liabilities

-39%

3Y+76.0%

5Y-82.0%

10Y+257.0%

1.64M

Total Equity

-114%

3Y-82.0%

5Y-102.0%

10Y-61.0%

Elicio Therapeutics, Inc. Funding & Solvency Profile

ELTX · NASDAQ

Current Assets

Cash & Cash Equivalents18.56M

Net Receivables0.00

Inventory0.00

Other Current Assets748.00K

Total Current Assets19 M

Non-Current Assets

Property, Plant & Equipment5.08M

Goodwill & Intangible Assets0.00

Long-Term Investments704.00K

Other Non-Current Assets770.00K

Total Non-Current Assets7 M

Total Assets

25.86M

Financial Health Analysis

Current Ratio

2.38x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

14.81x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

11 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

75% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Elicio Therapeutics, Inc. Balance Sheet

ELTX • NASDAQ

Elicio Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	18.6M	17.6M	12.9M	7.8M	88.8M	34.6M	5.6M	25.5M	2.1M	1.4M
Cash & Short-Term Investments	18.6M	17.6M	12.9M	7.8M	88.8M	34.6M	5.6M	25.5M	2.1M	1.4M
Net Receivables	0.0	0.0	0.0	0.0	806K	5M	440K	107K	485.8K	580.4K
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	5M	0.0	0.0	485.8K	580.4K
Other Receivables	0.0	0.0	0.0	0.0	806K	0.0	440K	107K	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	-63.7K	0.0	0.0	0.0
Prepaids	0.0	1.8M	2.6M	2.9M	1.3M	352K	319.1K	0.0	75.5K	79.4K
Other Current Assets	748K	1.3M	895K	36K	379K	360K	985.8K	60K	0.0	0.0
Total Current Assets	19.3M	20.7M	16.3M	10.7M	91.2M	40.3M	7.3M	25.7M	2.6M	2.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	5.1M	6.2M	7.3M	8.5M	4.4M	4.2M	1.4M	17K	6.2M	6.6M
Long-Term Investments	704K	696K	0.0	617K	723K	822K	999K	932K	1.7M	1.6M
Other Non-Current Assets	770K	600K	3.5M	2.8M	106K	2M	-843.9K	0.0	598.8K	734.4K
Total Non-Current Assets	6.6M	7.5M	10.8M	11.9M	5.3M	7M	1.6M	949K	8.4M	9M
Total Assets	25.9M	28.2M	27.1M	22.7M	96.5M	47.3M	8.8M	26.6M	11.1M	11M
LIABILITIES
CURRENT LIABILITIES
Total Payables	672K	1M	4.4M	2.8M	4.7M	5.6M	529.5K	534K	119.6K	300.5K
Accounts Payable	672K	1M	4.4M	2.8M	4.7M	5.6M	529.5K	534K	37.6K	209.5K
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	82K	91K
Accrued Expenses	0.0	6.1M	1.9M	1.5M	0.0	3.2M	2.1M	0.0	0.0	0.0
Short Term Debt	1M	901K	0.0	692K	952K	80.6M	6.9M	0.0	122.2K	115.6K
Capital Lease Obligations (Current)	0.0	0.0	910K	0.0	0.0	0.0	428.2K	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	82K	91K
Deferred Revenue	0.0	1.2M	0.0	1.4M	2.3M	3.9M	-428.2K	19K	82K	91K
Other Current Liabilities	6.4M	2.3M	2.6M	444K	3.3M	14.2M	-7.8M	6.8M	905.1K	688.3K
Total Current Liabilities	8.1M	11.5M	9.8M	6.9M	11.3M	107.4M	1.7M	7.4M	1.1M	1.1M
NON-CURRENT LIABILITIES
Long Term Debt	9.4M	20M	0.0	0.0	0.0	635K	0.0	0.0	5.2M	5.3M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	25.9M	0.0	362K	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4K	113K
Other Non-Current Liabilities	2.6M	2.8M	11K	92K	0.0	0.0	41.5M	0.0	250K	250K
Total Non-Current Liabilities	16.1M	28M	6M	6.9M	3.7M	30.3M	42M	362K	5.5M	5.7M
Capital Lease Obligations	4.1M	5.1M	6.9M	6.8M	3.7M	3.8M	867.6K	0.0	0.0	0.0
Total Liabilities	24.2M	39.5M	15.8M	13.7M	15M	137.8M	43.7M	7.7M	6.6M	6.8M
SHAREHOLDERS' EQUITY
Treasury Stock	-150K	-150K	-150K	0.0	0.0	-1.8M	-1.8M	-1.5M	0.0	0.0
Preferred Stock	25.9M	0.0	0.0	111.1M	70.4M	0.0	41.5M	0.0	0.0	0.0
Common Stock	178K	110K	96K	3K	300K	156K	95K	94K	612.0	612.0
Additional Paid-In Capital	235.4M	183M	153.8M	4.9M	0.0	72.1M	1.7M	60.1M	0.0	0.0
Retained Earnings	-233.7M	-194.1M	-142.2M	-107M	-215.1M	-160.6M	-80.5M	-39.8M	2.3M	1.7M
Accumulated Other Comprehensive Income/Loss	-127K	-175K	-197K	0.0	-103K	-333K	-313.9K	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	226M	0.0	18.4M	0.0	5.2K	5.2K
Total Stockholders' Equity	1.6M	-11.3M	11.4M	8.9M	81.5M	-90.4M	-18.6M	18.9M	2.3M	1.7M
Total Equity	1.6M	-11.3M	11.4M	8.9M	81.5M	-90.4M	-34.9M	18.9M	4.5M	4.2M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1M	2.5M
SUMMARY
Total Liabilities & Equity	25.9M	28.2M	27.1M	22.7M	96.5M	47.3M	8.8M	26.6M	11.1M	11M
Total Investments	704K	696K	0.0	617K	723K	822K	999K	932K	1.7M	1.6M
Total Debt	14.5M	26M	6.9M	7.5M	4.7M	85M	867.6K	0.0	5.3M	5.4M
Net Debt	-4.1M	8.4M	-6M	-316K	-84.1M	50.4M	-5.9M	-25.5M	3.3M	4M
Shares Outstanding	16,338,284	16,338,284	16,338,284	16,338,284	16,338,284	16,338,284	16,338,284	16,338,284	16,338,284	16,338,284

SEC Filings

ELTX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 29, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 16, 2026	March 16, 2026	2026	View Filing
S-3/A S-3/A (Amended) N/A	March 12, 2026	March 12, 2026		View Filing
10-K 10-K 2025 FY FY	March 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
S-3/A S-3/A (Amended) N/A	March 02, 2026	March 02, 2026		View Filing
S-3 S-3 N/A	February 27, 2026	February 27, 2026		View Filing
S-3 S-3 N/A	November 13, 2025	November 13, 2025		View Filing

Showing 1 to 10 of 122 filings

Related Guides

Blog Categories

Continue your ELTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.